Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants

Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepant...

Full description

Saved in:

Bibliographic Details
Published in:	Revue neurologique Vol. 177; no. 7; pp. 827 - 833
Main Authors:	Do, T.P., Al-Saoudi, A., Ashina, M.
Format:	Journal Article
Language:	English
Published:	Elsevier Masson SAS 01-09-2021
Subjects:	ASIC CGRP Ditan Gepant Glutamate Headache Ion channel Neurostimulation Orexin PACAP Prevention Preventive Serotonin TRP channel Preventive Headache PACAP Serotonin Glutamate Ion channel Prevention TRP channel ASIC Ditan Neurostimulation CGRP Gepant Orexin
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in development, including compounds targeting G-protein coupled receptors, glutamate, ion channels, and neuromodulatory devices. Emergence of these new interventions could complement our current treatment armamentarium for migraine management.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0035-3787
DOI:	10.1016/j.neurol.2021.06.005